Could a new oral drug change future treatments? early safety trial begins

NCT ID NCT07765498

Not yet recruiting Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This early-stage trial is testing an investigational drug called LY4355756 in healthy volunteers to see how safe it is and how the body absorbs it. Participants will receive the drug as an oral capsule or tablet, with some also receiving midazolam to check for drug interactions. The study involves several short stays at a research unit to monitor safety and drug levels. The goal is to gather essential safety data to support further development of this potential medicine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY4355756, an investigational drug given as an oral capsule or tablet
What this could lead to: If successful, this early study could pave the way for further testing of LY4355756 as a potential treatment for future conditions.
What could go wrong: This is a very early, small study focused on safety and drug processing in healthy people, not on treating any disease. The drug may not prove safe or effective in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Fortrea Clinical Research Unit

Dallas, Texas, 75247, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.